Considerations on the invasive management of ischemic and structural heart disease during the COVID-19 coronavirus outbreak. Consensus statement of the Interventional Cardiology Association and the Ischemic Heart Disease and Acute Cardiac Care Association of the Spanish Society of Cardiology

Rafael Romaguera, a, 1, Ignacio Cruz-González, b,1 Alfonso Jurado-Román, c,1 Soledad Ojeda, d Agustín Fernández-Cisnal, e Pablo Jorge-Pérez, f Virginia Burgos-Palacios, g Albert Ariza-Solé, a Esteban López-de-Sá, c and Raúl Moreno c, o

a Servicio de Cardiología, Hospital Universitario de Bellvitge, IDIBELL, L’Hospitalet de Llobregat, Universitat de Barcelona, Barcelona, Spain
b Servicio de Cardiología, Hospital Universitario de Salamanca, IBSAL, Salamanca, Spain
c Servicio de Cardiología, Hospital Universitario La Paz, Madrid, Spain
d Servicio de Cardiología, Hospital Universitario Reina Sofia, Córdoba, Spain
e Servicio de Cardiología, Hospital Clínico Universitario de Valencia, Valencia, Spain
f Servicio de Cardiología, Complejo Hospitalario Universitario de Canarias, Tenerife, Santa Cruz de Tenerife, Spain
g Servicio de Cardiología, Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain

ABSTRACT

The current COVID-19 outbreak is forcing healthcare workers to continuously reconsider the proper indications for cardiac catheterization. Human and material resources optimization, infection prevention for patients and healthcare workers, and transfer times force a rethink of the previously established protocols. This article is a consensus statement of the Interventional Cardiology Association and the Ischemic Heart Disease Association of the Spanish Society of Cardiology and aims to provide information to healthcare workers on the indications of diagnostic or therapeutic cardiac catheterization during the current COVID-19 pandemic.


Consideraciones sobre el abordaje invasivo de la cardiopatía isquémica y estructural durante el brote de coronavirus COVID-19. Documento de consenso de la Asociación de Cardiología Intervencionista y la Asociación de Cardiopatía Isquémica y Cuidados Águdos Cardiovasculares de la Sociedad Española de Cardiología

RESUMEN

El brote actual de COVID-19 está obligando a los profesionales sanitarios a replantear de forma continua las indicaciones de cateterismo cardíaco. La optimización de recursos materiales y humanos, la prevención de contagios a profesionales y pacientes, así como la gestión de los tiempos de traslado, hace totalmente necesario reformular los protocolos previamente establecidos. El presente texto es un documento de consenso de la Asociación de Cardiología Intervencionista y la Asociación de Cardiopatía Isquémica y Cuidados Águdos Cardiovasculares de la Sociedad Española de Cardiología que pretende dar información al personal sanitario sobre las indicaciones de cateterismo diagnóstico o terapéutico durante la pandemia actual de COVID-19.


1 R. Romaguera, I. Cruz-González, and A. Jurado-Román contributed equally to this work as lead authors.

© The undersigned authors are affiliated to the following scientific bodies: Spanish Society of Cardiology Working Group on Cardiac Catheterization and Interventional Cardiology: R. Romaguera [chair], I. Cruz-González [president-elect], S. Ojeda [chair], and R. Moreno [president]. Spanish Society of Cardiology Working Group on Ischemic Heart Disease and Acute Cardiovascular Care: E. López-de-Sá [president], A. Ariza-Solé [president-elect], P. Jorge-Pérez [chair], and V. Burgos-Palacios [chair].

* Corresponding author: Servicio de Cardiología, Hospital Universitario de Bellvitge, Feixa Llarga s/n, 08907 L’Hospitalet de Llobregat, Barcelona, Spain.
E-mail address: rafaromaguera@gmail.com (R. Romaguera).

https://doi.org/10.24875/RECICE.M20000121
2604-7322 / © 2020 Sociedad Española de Cardiología. Published by Permanyer Publications. This is an open access journal under the CC BY-NC-ND 4.0 license.

Please cite this article in press as: Romaguera R, et al. Considerations on the invasive management of ischemic and structural heart disease during the COVID-19 coronavirus outbreak. Consensus statement of the Interventional Cardiology Association and the Ischemic Heart Disease and Acute Cardiac Care Association of the Spanish Society of Cardiology. REC Interv Cardiol. 2020. https://doi.org/10.24875/RECICE.M20000121
INTRODUCTION

The current outbreak of COVID-19 has caused all healthcare providers to rethink the indications for cardiac catheterization on an ongoing basis. The optimization of material and human resources, the prevention of contagions to healthcare providers and patients, and management during patient transfers makes it absolutely necessary to reformulate the protocols previously established. This consensus document has been agreed by the Interventional Cardiology Working Group on Cardiac Catheterization and Interventional Cardiology (ACI-SEC) and the Spanish Society of Cardiology Working Group on Ischemic Heart Disease and Acute Cardiovascular Care. It includes indications to perform cardiac catheterizations under the current situation. It is difficult to foresee the evolution of this pandemic and its health impact, which will probably force us to readjust this document based on the particular situation and dynamic of each center. It is important to emphasize that when the actual situation is over, we recommend going back to the indications included in the clinical practice guidelines published by the European Society of Cardiology.1

In order to perform cardiac catheterizations our advice is to follow the recommendations on prevention and management included in the consensus document published by the ACI-SEC and the Heart Rhythm Association of the Spanish Society of Cardiology.2

ELECTIVE PROCEDURES

Indication for elective procedures in the catheterization laboratory should be based on individual assessments of the risk of contagion/benefit from the intervention ratio. In the current situation postponing all elective procedures seems the most reasonable thing to do to minimize the possibility of contagion of disease-free patients (and people they may have been in contact with) in a setting of high prevalence of COVID-19 infection such as hospitals. Similarly, performing right catheterizations during this pandemic is ill-advised.

If the cath lab has enough material and human resources, the non-emergent catheterizations of already hospitalized patients without suspicion of COVID-19 or COVID-19-negative patients may be an option to promote early discharges (i.e., a study to characterize dilated cardiomyopathy in a patient admitted with an index episode of heart failure).

NON-ST-SEGMENT ELEVATION ACUTE CORONARY SYNDROME

Differential diagnosis

A key element to be taken into consideration when indicating a cardiac catheterization in a patient with acute coronary syndrome (ACS) is the high prevalence of heart disease in patients admitted due to COVID-19, the significantly high troponin levels (8% to 12% higher) seen in confirmed cases of COVID-19 but without ACS yet, and the possibility that myocarditis complicates the COVID-19 infection. This highlights the importance of clinical judgement before establishing a diagnosis of ACS/acute myocardial infarction. In general, in patients hospitalized due to COVID-19 infection who experience high cardiac enzyme levels of coronary origin and remain asymptomatic we recommend following a conservative approach. Coronary angiography should be spared for cases of high suspicion of high-risk ACS, medical treatment-resistant recurrent ischemia, and when the patient’s vital prognosis following the infection anticipates good prognosis.

NON-ST-SEGMENT ELEVATION ACUTE CORONARY SYNDROME

Figure 1 shows the approach suggested for patients with non-ST-segment elevation acute coronary syndrome (NSTEACS). In patients hospitalized due to NSTEACS with suspicion of COVID-19 we recommend running the diagnostic test before performing the cardiac catheterization to assess the risk/benefit ratio of the procedure. The current clinical guidelines on revascularization recommend an early invasive strategy (<24 h) in patients with at least 1 criterion of high risk and in <72 h in patients with at least 1 criterion of intermediate risk.6 In most of the patients with NSTEACS this interval should be enough to confirm or discard the infection. The procedure should be postponed if the patient’s clinical situation allows it in cases where the diagnostic test is not available yet. On the contrary, in patients with NSTEACS but with persistent ischemia or high-risk criteria like recurrent angina, diffuse ST-segment changes suggestive of left main coronary artery or ventricular dysfunction performing the catheterization within the first 2 hours may be an option, taking the necessary protective measures to avoid transmitting the infection.

Patients negative for COVID-19 undergoing the procedure should be discharged early from the hospital.

In patients admitted to centers without a cath. lab. who need to be transferred, it is advisable, if possible, to follow a conservative approach and early discharge except for high-risk criteria or poor disease progression.

In selected patients with acute myocardial infarction—especially type 2—the conservative approach is the one recommended initially.

Revascularization in NSTEACS and multivessel disease

In patients with NSTEACS and multivessel disease and an indication for complete revascularization who remain hospitalized in centers where surgeries have been postponed, we recommend performing it within the same procedure to reduce hospital stay and avoid having to perform another procedure in the cath. lab.

ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION

The reperfusion treatment during the management of ST-segment elevation myocardial infarction (STEMI) of <12 hour-duration since symptom onset should be the primary percutaneous coronary intervention (pPCI) because it reduces the rates of mortality, reinfarction, stroke, and mechanical complications compared to fibrinolysis. Also, a significant percentage of patients undergoing pPCI can be discharged early and don’t require further invasive examinations which simplifies the management of these patients. This reduces the hospital stay and avoids collapsing the entire healthcare system. Nevertheless, during the COVID-19 pandemic the following key points should be taken into consideration:

- Due to the current care overload sustained by the ERs of our healthcare system, transfer times can take longer than usual in many cases.

- The transfer of patients with suspicion or confirmation of COVID-19 should take place safely and with infection under control. Also, after the transfer the ambulance should be properly disinfected. Therefore, the logistics required to guarantee safe transfers can also delay the entire process.
Despite the preventive measures implemented to avoid transmitting the infection, the transfer of patients with an active infection for COVID-19 to a different center can infect the healthcare providers and, most important of all, other patients hospitalized and who are especially vulnerable to the disease.

In patients already diagnosed with COVID-19 and in poor clinical state (especially patients hospitalized in intensive care units) with STEMI, reperfusion treatment may yield no clinical benefits.

Reperfusion strategy

Figure 2 shows the management of STEMI. The ACI-SEC and the Spanish Society of Cardiology Working Group on Ischemic Heart Disease and Acute Cardiovascular Care recommend that the percutaneous coronary intervention should be the reperfusion strategy of choice in most cases. Fibrinolysis should be spared for cases diagnosed in non-PCI capable centers that meet one of the following requirements:

- Estimated time to the pPCI > 120 min.
- Patients who have tested positive to COVID-19 with poor clinical state that makes transfer difficult.
- Patients who have tested positive to COVID-19 with low hemorrhagic risk and symptoms of < 3 hour-duration.

In cases where fibrinolysis may be an option, the lack of contraindications and the administration of the drug in < 10 min from diagnosis should be guaranteed. Then, depending on the patient’s clinical state and the availability of beds in the ICU of the destination hospital, transfer to a center with cath. lab. capabilities may be considered. The rule of thumb here is to avoid transferring patients with confirmed reperfusion and good disease progression.

After the percutaneous coronary intervention, it is recommended that each patient be taken to their referring centers. However, the patients’ clinical situation and bed availability of each center should be individualized in each case.

Other considerations

As a general rule we recommend leaving the number of centers that are part of the infarction code program untouched. Although demand from out-of-hospital emergency medical services may change significantly during the COVID-19 pandemic, a hospitalized patient may have an indication for an urgent cardiac catheterization. In the current situation, transferring this patient to a different center may be more problematic than performing the procedure at the center where the patient is already hospitalized. Our recommendation here is that no PCI capable center should avoid treating infarctions.

Other clinical considerations:

- The diagnosis of STEMI in patients with complete left bundle-branch block is still complex to this day despite the use of different electrocardiographic criteria. Therefore, in patients with suspicion or confirmation of COVID-19 who require transfer for reperfusion we recommend agreeing on the diagnosis as much as possible to avoid unnecessary transfers.
The following key points should be taken into consideration:

- As in the rest of patients with cardiogenic shock, only the culprit vessel should be revascularized.11
- If intubation is necessary and possible, it should be performed before entering the cath. lab. and in the best conditions possible to comply with all COVID-19 prevention recommendations.
- Connection to a ventilator—a closed system—is recommended prior to manual ventilation with an ambu-bag. If ventilation with manual resuscitation is necessary, the use of high-efficiency particulate air (HEPA) filters between the tube and the bag is recommended.
- The extracorporeal membrane oxygenation (ECMO) machine used by the heart team should be purged at all times before the arrival of patients to reduce the possibility of infection and spread up the whole process. In patients with COVID-19 with cardiogenic shock, ECMO can be used as the first-line therapy compared to other devices like the Impella ventricular support system or the intra-aortic balloon pump counterpulsation.

STRUCTURAL HEART INTERVENTIONS

In general, all structural heart interventions should be postponed until the pandemic is under control. We should remember that most of these procedures require several days at the hospital, but at the same time the ICU/coronary unit beds may become necessary for patients with COVID-19. Also, in some cases structural heart interventions are performed under general anesthesia and intubation or on transesophageal echocardiography monitoring. All of them high-risk situations for the infection of patients and healthcare providers. On the other hand, patients undergoing structural heart interventions are often old and therefore especially susceptible to nosocomial infection due to COVID-19.

Other urgent procedures like aortic valvuloplasty or transcatheter aortic valve implantation in patients with angina at rest, recurrent syncope or refractory heart failure can be performed.

DRUGS

Regarding the drugs commonly used at the catheterization laboratory such as antithrombotic therapies, the recommendations are basically the same regardless of whether the patient has been infected with COVID-19 or not.

The medication to treat patients with COVID-19 may interact with the most common drugs currently used at the cath. lab.12

Figure 3 shows the most commonly used drugs in cardiology both in the context of ACS and stable coronary artery disease.

Antiplatelet therapy

- Adiro: no evidence of significant interactions.
- Oral P2Y12 platelet receptor antagonists: prioritize prasugrel. Concomitant treatment with lopinavir/ritonavir or darunavir/cobicistat increases the effect of ticagrelor and can reduce the effect of clopidogrel.
- Cangrelor: no evidence of significant interactions.
- Tirofiban: no evidence of significant interactions.
Anticoagulant drugs
- Unfractionated heparin: no evidence of significant interactions.
- Bivalirudin: no evidence of significant interactions.
- Enoxaparin: no evidence of significant interactions.
- Fondaparinux: no evidence of significant interactions.

Analgesics/sedatives
- Fentanyl/morphine: potential interactions; prioritize morphine.
- Midazolam: it should not be administered orally. It can be IV administered with special caution.

Antithrombotic drugs
<table>
<thead>
<tr>
<th>Acetylsalicylic acid</th>
<th>Clopidogrel</th>
<th>Ticagrelor</th>
<th>Prasugrel</th>
<th>Heparines</th>
<th>Enoxaparin</th>
<th>Fondaparinux</th>
<th>Dalteparine</th>
<th>Dabigatran</th>
<th>Edoxaban</th>
<th>Rivaroxaban</th>
<th>Streptokinase</th>
</tr>
</thead>
</table>

Antihypertensive drugs/HFD
<table>
<thead>
<tr>
<th>ACEI</th>
<th>Captopril</th>
<th>Enalapril</th>
<th>Lisinopril</th>
<th>ACE II antagonists</th>
<th>Candesartan</th>
<th>Irbesartan</th>
<th>Losartan</th>
<th>Valsartan</th>
<th>Amlodipine</th>
<th>Diltiazem</th>
<th>Nifedipine</th>
<th>Verapamil</th>
</tr>
</thead>
</table>

Diuretics/other
<table>
<thead>
<tr>
<th>Furosemide</th>
<th>Torasemide</th>
<th>Eplerenone</th>
<th>Hydrochlorothiazide</th>
<th>Digoxin</th>
<th>Isosorbide dinitrate</th>
<th>Ivalbutenine</th>
<th>Ramolazine</th>
</tr>
</thead>
</table>

Hypolipemiant drugs
<table>
<thead>
<tr>
<th>Atorvastatin</th>
<th>Pitavastatin</th>
<th>Rosuvastatin</th>
<th>Simvastatin</th>
<th>Ezetimib</th>
<th>Gemfibrozil</th>
<th>Fenofibrate</th>
<th>Evolocumab</th>
</tr>
</thead>
</table>

Inotropes and vaspressors
- Adrenaline: no evidence of significant interactions.
- Dobutamine: no evidence of significant interactions.
- Noradrenaline: no evidence of significant interactions.
- Dopamine: no evidence of significant interactions.

Other
- Nitroglycerin: no evidence of significant interactions.
- Verapamil: potential interactions. Administer and use with special caution and close monitoring.
- Furosemide: no evidence of significant interactions.

Figure 3. Possible interactions between the most commonly used drugs in cardiology and the possible treatments used against COVID-19. ACE II, angiotensin-converting enzyme antagonists; ACEI, angiotensin-converting enzyme inhibitors; CCB, calcium channel blockers; DOAC, direct-acting oral anticoagulants; HFD, heart failure drugs.
CONCLUSIONS

The current outbreak of COVID-19 has made us rethink the invasive approach to ischemic and structural heart disease. The recommendation of the Spanish Society of Cardiology Working Groups on Cardiac Catheterization and Interventional Cardiology and Ischemic Heart Disease and Acute Cardiovascular Care is to postpone all non-emergent procedures to avoid the infection of patients and healthcare providers and minimize the collapse of the healthcare system. However, the percutaneous coronary intervention should still be used for the management of ST-segment elevation myocardial infarction unless prescribed otherwise.

CONFICTS OF INTEREST

The authors have declared no conflicts of interest regarding this manuscript. R. Moreno is associate editor of REC: Interventional Cardiology. The journal’s editorial procedure to ensure impartial handling of the manuscript has been followed.

EDITOR’S NOTE

This manuscript has undergone an especially rapid internal review by the editorial team due to the strong interest in disseminating the information among the scientific community. The editors thank Permanyer Publications for their collaboration and commitment to the prompt publication of this document.

REFERENCES